A Study of the Safety of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program for use in Stem Cell Transplants to Unrelated People


About this study

The purpose of this study is to evaluate the safety of using unlicensed cord blood units from the National Cord Blood Program in unrelated  patients needing stem cell transplants, by carefully documenting all infusion-related problems.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Have disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment
  • Any age and either gender
  • Using a cord blood product manufactured by the National Cord Blood Program (at least one, if the graft contains more than one unit)

Exclusion Criteria

  • Are only receiving licensed cord blood products
  • Are only receiving unlicensed cord blood products from other banks
  • Are being transplanted at non-US transplant centers
  • Are receiving cord blood products that will be "manipulated" post-thaw (e.g., ex vivo expansion, incubation in vitro, etc.)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

William Hogan, M.B., B.Ch.

Open for enrollment

Contact information:

Joni Amundson



More information


Publications are currently not available

Mayo Clinic Footer